流感最新消息N°551

GLOBAL INFLUENZA SURVEILLANCE AND RESPONSE SYSTEM (GISRS) RSV SARS-CoV-2 Influenza Co-circulation SUMMARY (Based on data reported to WHO for week 43, ending 26 October 2025) Globally, influenza and SARS-CoV-2 activity remained low in week 43. SARS-CoV-2 predominated in the temperate and subtropical regions of the northernhemisphere. Influenza was predominant in the tropics, with positivity around 10% and over 10% in the temperate and subtropical areas of the southernhemisphere. [Figures 1a, 1b, 1c and 1d] . qInfluenza Globally, influenza activity remained low, with influenza A viruses continuing to predominate. [Figure 2] In the northern hemisphere, influenza activity remained low and stable in most countries. Influenza percent positivity was elevated in a few countriesin Central America and the Caribbean, Northern Europe, and Eastern Asia, and was over 30% in Western, Eastern and Middle Africa, Western,Southern and South-East Asia. Small increases in activity were observed in countries in Central America and the Caribbean, Western, Eastern andMiddle Africa, South West and Northern Europe, Western, Southern and South-East Asia. [Figures 3 and 4] In the southern hemisphere, influenza activity remained low and stable in most countries with elevated positivity (>10%) in single countries inTemperate South America and Eastern Africa and percent positivity over 30% in a single country in South-East Asia. A small increase in activity wasobserved in a single country in Temperate South America. [Figures 3 and 4] In the transmission zones with elevated positivity, influenza A(H1N1)pdm09 predominated in Central America and the Caribbean, Eastern andMiddle Africa whereas influenza A(H3N2) was predominant in Temperate South America, Northern Europe, Western, Southern and South-East Asia.Influenza A(H1N1)pdm09 and influenza A(H3N2) were codominant in Western Africa. [Figures 5 and 6] qSARS-CoV-2Globally, SARS-CoV-2 positivity increased but remained at low levels, with some countries reporting elevated positivity (>10%) in Central America and the Caribbean, Tropical and Temperate South America, Europe, and Eastern Asia. Percent positivity was over 30% in one country in EasternEurope. Small increases in activity were reported in single countries in Tropical South America, South-West Europe and in two countries in EasternEurope. [Figures 7 and 8] qRespiratory Syncytial Virus (RSV)RSV percent positivity remained elevated in single countries in Western and Eastern Africa and Eastern Asia, and over 30% in two countries in Central America and the Caribbean. RSV positivity remained stable across most countries, with increases in activity in a few countries in CentralAmerica and the Caribbean and one country in South West Europe. [Figures 9 and 10] RSV and influenza activity were both elevated in a fewcountries of Central America and the Caribbean and one country in Western Africa. Co-circulation of influenza and SARS-CoV-2 1a) Weekly numbers of influenza and SARS-CoV-2 virus specimens tested and percent positivity at the global level(last 12 months) 1c) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Tropical areas 1b) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Northern hemispheretemperate and subtropical areas 1d) Weekly numbers of influenza andSARS-CoV-2 virus specimens tested andpercent positivity in Southern hemispheretemperate and subtropical areas Influenza 2) Weekly numbers of influenza virus positive specimens by type and subtype and percent positivity at the globallevel (last 12 months) 4) Change in proportions of specimens that testedpositive for influenza (year-week:2025-43) 3) Proportions of specimens that tested positive forinfluenza (year-week:2025-43) 6) Weekly distribution of influenza virus types andsubtypes by geographic zone (last 12 months) 5) Proportions of influenza virus types and subtypes byinfluenza transmission zones (year-week:2025-43) SARS-CoV-2 7) Proportions of specimens that tested positive forSARS-CoV-2 (year-week:2025-43) 8) Change in proportions of specimens that testedpositive for SARS-CoV-2 (year-week:2025-43) Respiratory syncytial virus 9) Proportions of specimens that tested positive for RSV(year-week:2025-43) 10) Change in proportions of specimens that testedpositive for RSV (year-week:2025-43) Additional information Data and methods The data presented in this report originates from virologic surveillance conducted by countries, areas, and territories (CATs) andsubmitted to WHO FluNet through participation or collaboration with the Global Influenza Surveillance and Response System(GISRS). These CATs employ diverse methodologies to monitor respiratory virus activity, which may result in variations betweenthis report and other surveillance summaries published elsewhere. This report includes virologic data from bothsentinel surveillance and other systematically conducted